Q2 2023

Filed Feb 13, 2023 · 10-Q · 44 days after period end · 0001193125-23-034339

Q2 2023 · 10-Q

Revenue

$14.00K

−44.0% vs Q2 2022

Net Income

-$5.41M

N/M vs Q2 2022

EPS Diluted

-$3.34

N/M vs Q2 2022

Operating Income-$5,610,000N/M

Operating Cash Flow

Same quarter

Metric	Q2 2023	Q2 2022	Q2 2021	Q2 2020
Revenue	$14.00K	$25.00K	$1.00K	$77.00K
Net Income	-$5.41M	-$4.82M	-$3.25M	-$2.09M
EPS Diluted	-$3.34	-$0.59	-$0.76	-$2.00

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Benitec Biopharma Inc. · CIK 1808898 · Engraved from SEC EDGAR